Search
for
Sort by
Research 91–120 of 774
- Selective blockade of γc pathway ameliorates alopecia areata in a humanized murine model
- Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
- Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
- The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series
- A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
- Successful treatment of severe diffuse alopecia areata with abrocitinib
- 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
- Immunopathology and Immunotherapy of Inflammatory Skin Diseases
- Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil.
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
- Advances in the mechanism and new therapies of alopecia areata
- Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
- Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient